Steven M. Paul - 16 Feb 2022 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
President & CEO, Director
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
16 Feb 2022
Net transactions value
$0
Form type
4
Filing time
17 Feb 2022, 16:20:03 UTC
Previous filing
05 Jan 2022
Next filing
05 Apr 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Award $0 +146,900 $0.000000 146,900 16 Feb 2022 Common Stock 146,900 $111.97 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options shall vest on February 16, 2023, and the remaining options shall vest in twelve equal three-month installments over the following three years, subject to continued service through such dates.